miR-21 expression in pregnancy-associated breast cancer: A possible marker of poor prognosis

Journal of Cancer

Volumn 2, Issue 1, 2011, Pages 67-75

  Walter, Beatriz A ^a   Gómez Macias, Gabriela ^b   Valera, Vladimir A ^a   Sobel, Mark ^a   Merino, Maria J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

Author keywords

Breast cancer; microRNA; miR 21; Pregnancy associated breast cancer; PTEN

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MEMBRANE PROTEIN; MICRORNA 21; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE RECEPTOR; PROGRAMMED CELL DEATH 4; PROTEIN BCL 2; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE; PREGNANCY ASSOCIATED BREAST CANCER; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION;

EID: 80054856081     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.2.67     Document Type: Article

References (32)

1. Petrek JA. Breast cancer and pregnancy. Journal of the National Cancer Institute; 1994;(16):113-121.
2. Ulery M, Carter L, McFarlin BL, Giurgescu C. Pregnancy-associated breast cancer: significance of early detection. Journal of midwifery & women's health; 2009;54(5):357-363.
3. Pentheroudakis G, Pavlidis N. Cancer and pregnancy: poena magna, not anymore. Eur J Cancer; 2006;42(2):126-140.
4. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell; 1993;75(5):843-854.
5. Sassen S, Miska EA, Caldas C. MicroRNA: implications for cancer. Virchows Arch; 2008;452(1):1-10.
6. Miska EA. How microRNAs control cell division, differentiation and death. Current opinion in genetics & development; 2005;15(5):563-568.
7. Gaur A, Jewell DA, Liang Y et al. Characterization of micro-RNA expression levels and their biological correlates in human cancer cell lines. Cancer research;2007;67(6):2456-2468.
8. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nature reviews; 2006;6(4):259-269.
9. Lu J, Getz G, Miska EA et al. MicroRNA expression profiles classify human cancers. Nature; 2005;435(7043):834-838.
10. Selcuklu SD, Yakicier MC, Erson AE. An investigation of microRNAs mapping to breast cancer related genomic gain and loss regions. Cancer genetics and cytogenetics; 2009;189(1):15-23.
11. Selcuklu SD, Donoghue MT, Spillane C. miR-21 as a key regulator of oncogenic processes. Biochemical Society transactions; 2009;37(Pt 4):918-925.
12. Qi L, Bart J, Tan LP et al. Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma. BMC cancer; 2009;9:163.
13. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology; 2007;133(2):647-658.
14. Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, Krogh A, Lund AH. Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. The Journal of biological chemistry; 2008;283(2):1026-1033.
15. Yan LX, Huang XF, Shao Q et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA (New York, NY); 2008;14(11):2348-2360.
16. Chen Y, Gelfond JA, McManus LM, Shireman PK. Reproducibility of quantitative RT-PCR array in miRNA expression profiling and comparison with microarray analysis. BMC genomics; 2009;10:407.
17. Callagy GM, Pharoah PD, Pinder SE et al. Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clin Cancer Res; 2006;12(8):2468-2475.
18. Kroman N, Mouridsen HT. Prognostic influence of pregnancy before, around, and after diagnosis of breast cancer. Breast (Edinburgh, Scotland); 2003;12(6):516-521.
19. Bladstrom A, Anderson H, Olsson H. Worse survival in breast cancer among women with recent childbirth: results from a Swedish population-based register study. Clinical breast cancer; 2003;4(4):280-285.
20. Halaska MJ, Pentheroudakis G, Strnad P et al. Presentation, management and outcome of 32 patients with pregnancy-associated breast cancer: a matched controlled study. The breast journal; 2009;15(5):461-467.
21. Iorio MV, Casalini P, Tagliabue E, Menard S, Croce CM. MicroRNA profiling as a tool to understand prognosis, therapy response and resistance in breast cancer. Eur J Cancer; 2008;44(18):2753-2759.
22. Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY. miR-21-mediated tumor growth. Oncogene; 2007;26(19):2799-2803.
23. Bourguignon LY, Xia W, Wong G. Hyaluronan-mediated CD44 interaction with p300 and SIRT1 regulates beta-catenin signaling and NFkappaB-specific transcription activity leading to MDR1 and Bcl-xL gene expression and chemoresistance in breast tumor cells. The Journal of biological chemistry; 2009;284(5):2657-2671.
24. Huang GL, Zhang XH, Guo GL et al. Clinical significance of miR-21 expression in breast cancer: SYBR-Green I-based real-time RT-PCR study of invasive ductal carcinoma. Oncology reports; 2009;21(3):673-679.
25. [No authors listed]. The world Health Organization Histological Typing of Breast Tumors--Second Edition. The World Organization. American journal of clinical pathology; 1982;78(6):806-816.
26. Tsutsui S, Inoue H, Yasuda K et al. Reduced expression of PTEN protein and its prognostic implications in invasive ductal carcinoma of the breast. Oncology; 2005;68(4-6):398-404.
27. Chung MJ, Jung SH, Lee BJ, Kang MJ, Lee DG. Inactivation of the PTEN gene protein product is associated with the invasiveness and metastasis, but not angiogenesis, of breast cancer. Pathology international; 2004;54(1):10-15.
28. Koninki K, Barok M, Tanner M et al. Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells. Cancer letters 2010; 294(2):211-219.
29. Zhang S, Yu D. PI(3)King Apart PTEN's Role in Cancer. Clin Cancer Res. 2010;16(17):4325-30.
30. Lankat-Buttgereit B, Goke R. The tumour suppressor Pdcd4: recent advances in the elucidation of function and regulation. Biology of the cell; 2009;101(6):309-317.
31. Dawson SJ, Makretsov N, Blows FM et al. BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. British journal of cancer 2010; 103(5):668-675.
32. Hsiao YH, Su YA, Tsai HD, Mason JT, Chou MC, Man YG. Increased invasiveness and aggressiveness in breast epithelia with cytoplasmic p63 expression. International journal of biological sciences 2010; 6(5):428-442.